FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

<b>Nashington</b>	D.C. 20549	

STATEMENT	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MEHTA VIREN					2. Issuer Name <b>and</b> Ticker or Trading Symbol Onconova Therapeutics, Inc. [ ONTX ]							ck all applica Director	10% Owner		ner	
				07	3. Date of Earliest Transaction (Month/Day/Year) 07/09/2020							Officer (g			Other (sp below)	
(Street) NEWTOW		1	.8940 Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			action 2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.			5. Amount Securities Beneficiall Owned Fol Reported	Form: y (D) or		Direct In ndirect Br. 4) O	'. Nature of ndirect Beneficial Ownership Instr. 4)				
						Code V	Amount	(A) or (D)	Price	Transactio (Instr. 3 an						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security  (Instr. 3)  2. Conversion On Exercise Price of Derivative Security  (Month/Day/Year)  3. Transaction Date Execution Date, (Month/Day/Year)  (Month/Day/Year)		Code	ransaction Derivative Securities		re s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title ar of Securi Underlyin Derivative (Instr. 3 a		g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Appreciation Right	\$0.56	07/09/2020		A		125,000		07/09/2021 <sup>(1)</sup>	07/09/2030	Common Stock	125,000	\$0	125,00	0	D	

## **Explanation of Responses:**

1. These stock appreciation rights vest 100% on the first anniversary of the grant date.

/s/ Mark Guerin as attorney-in-

fact

07/10/2020

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.